Polyclonal Antibody to Alkaline Phosphatase (ALP) | MyBioSource MBS2004938 product information

product summary

company name :

MyBioSource

product type :

antibody

product name :

Polyclonal Antibody to Alkaline Phosphatase (ALP)

catalog :

MBS2004938

quantity :

0.01 mg

price :

90 USD

clonality :

polyclonal

host :

rabbit

conjugate :

reactivity :

human

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation

more info or order :

MyBioSource product webpage

image

image 1 :

Western Blot: Sample: Recombinant ALP, Bovine.

product information

catalog number :

MBS2004938

products type :

Antibody

products full name :

Polyclonal Antibody to Alkaline Phosphatase (ALP)

products short name :

[Alkaline Phosphatase (ALP)]

other names :

[alkaline phosphatase; Alkaline phosphatase, tissue-nonspecific isozyme; alkaline phosphatase, tissue-nonspecific isozyme; glycerophosphatase; tissue-nonspecific ALP; alkaline phosphomonoesterase; liver/bone/kidney-type alkaline phosphatase; alkaline phosphatase liver/bone/kidney isozyme; alkaline phosphatase, liver/bone/kidney; Alkaline phosphatase liver/bone/kidney isozyme]

products gene name :

[ALP]

other gene names :

[ALPL; ALPL; HOPS; TNAP; APTNAP; TNSALP; AP-TNAP; AP-TNAP; TNSALP]

uniprot entry name :

PPBT_HUMAN

clonality :

polyclonal

host :

rabbit

purity :

Antigen-specific affinity chromatography followed by Protein A affinity chromatography

form :

Supplied as solution form in 0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.

concentration :

0.59mg/ml

storage stability :

Storage: Avoid repeated freeze/thaw cycles. Store at 4ºC for frequent use. Aliquot and store at -20ºC for 24 months. Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

tested application :

Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunoprecipitation (IP)

app notes :

Western blotting: 0.5-2ug/mL;. Immunohistochemistry: 5-20ug/mL;. Immunocytochemistry: 5-20ug/mL;. Optimal working dilutions must be determined by end user.

image1 heading :

Western Blot (WB)

other info1 :

Organism Species: Bos taurus; Bovine (Cattle). Source: Polyclonal antibody preparation. Traits: Liquid. Immunogen: Recombinant ALP (Leu18~Arg335) expressed in E.coli ( MBS2104731 )

ncbi gi num :

178462

ncbi acc num :

AAB59378.1

uniprot acc num :

P05186

ncbi pathways :

AGE/RAGE Pathway (698754); BDNF Signaling Pathway (712093); Endochondral Ossification Pathway (198812); Folate Biosynthesis Pathway (83018); Folate Biosynthesis Pathway (404); TNF-alpha/NF-kB Signaling Pathway (198884)

ncbi summary :

There are at least four distinct but related alkaline phosphatases: intestinal, placental, placental-like, and liver/bone/kidney (tissue non-specific). The first three are located together on chromosome 2, while the tissue non-specific form is located on chromosome 1. The product of this gene is a membrane bound glycosylated enzyme that is not expressed in any particular tissue and is, therefore, referred to as the tissue-nonspecific form of the enzyme. The exact physiological function of the alkaline phosphatases is not known. A proposed function of this form of the enzyme is matrix mineralization; however, mice that lack a functional form of this enzyme show normal skeletal development. This enzyme has been linked directly to hypophosphatasia, a disorder that is characterized by hypercalcemia and includes skeletal defects. The character of this disorder can vary, however, depending on the specific mutation since this determines age of onset and severity of symptoms. Alternatively spliced transcript variants have been described. [provided by RefSeq, Apr 2010]

uniprot summary :

ALPL: This isozyme may play a role in skeletal mineralization. Defects in ALPL are a cause of hypophosphatasia (HOPS). HOPS is an inherited metabolic bone disease characterized by defective skeletal mineralization. Four hypophosphatasia forms are distinguished, depending on the age of onset: perinatal, infantile, childhood and adult type. The perinatal form is the most severe and is almost always fatal. Patients with only premature loss of deciduous teeth, but with no bone disease are regarded as having odontohypophosphatasia (odonto). Defects in ALPL are a cause of hypophosphatasia childhood type (HOPSC). Defects in ALPL are a cause of hypophosphatasia infantile type (HOPSI). Belongs to the alkaline phosphatase family. 3 isoforms of the human protein are produced by alternative splicing. Protein type: Motility/polarity/chemotaxis; EC 3.1.3.1; Cofactor and Vitamin Metabolism - folate biosynthesis; Phosphatase (non-protein); Membrane protein, GPI anchor. Chromosomal Location of Human Ortholog: 1p36.12. Cellular Component: extracellular matrix; extracellular space; membrane; plasma membrane; integral to membrane. Molecular Function: pyrophosphatase activity; protein binding; alkaline phosphatase activity; metal ion binding. Biological Process: response to antibiotic; osteoblast differentiation; response to vitamin D; dephosphorylation; response to glucocorticoid stimulus; reproductive developmental process; response to lipopolysaccharide; skeletal development; endochondral ossification. Disease: Hypophosphatasia, Infantile; Hypophosphatasia, Adult; Hypophosphatasia, Childhood

size1 :

0.01 mg

price1 :

90 USD

size2 :

0.02 mg

price2 :

105

size3 :

0.05 mg

price3 :

140

size4 :

0.1 mg

price4 :

175

size5 :

0.2 mg

price5 :

245

size6 :

1 mg

price6 :

565

more info or order :

MyBioSource product webpage